Insiders Trades

★ Sign in to follow

WL

Winifred L. Swan

Executive

US·SEC (Form 4)

NxStage Medical, Inc.

Cumul. flow

Total declarations

254

Company

1

▲ Purchases (0 ops.)

—

▼ Sales (113 ops.)

€8.4M

Latest filing published 25 Feb 2019 for NxStage Medical, Inc., €346k.

Filing timeline

BuySale

Winifred L. Swan

First 200 filings with a declared amount

Insider track record

Disclosed buys

0

Disclosed sells

113

Signal history

Winifred L. Swan: trading record in brief

Winifred L. Swan discloses dealings in NxStage Medical, Inc. to SEC (Form 4). Over a trading history stretching from 27 November 2006 to 21 February 2019, the count stands at 254 filings.

Sales make up the whole of the open-market record (113 sales, €8.4M). Besides market trades, the filings include 24 share grants and 116 option exercises.

The newest entry dates from 25 February 2019: a transaction of €346k, in NxStage Medical, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Winifred L. Swan

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

NxStage Medical, Inc. (US)

Declarations250 total

●

Winifred L. Swan

SVP and General CounselExecutives21 Feb 2019NxStage Medical, Inc.

392,310 USD17SEC

13,077 shares@ US$30.0062.8% of flowCommon StockSEC:0001246360-19-000765:0

◇

Winifred L. Swan

SVP and General CounselExecutives9 Mar 2018NxStage Medical, Inc.

0SEC

4,657 shares0Common StockSEC:0001246360-18-001074:0

◆

Winifred L. Swan

SVP and General CounselExecutives9 Mar 2018NxStage Medical, Inc.

32,900 USD11SEC

1,350 shares@ US$24.370.8% of flowCommon StockSEC:0001246360-18-001074:1

◇

Winifred L. Swan

SVP and General CounselExecutives20 Feb 2018NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-18-000793:0

▼

Winifred L. Swan

SVP and General CounselExecutives20 Feb 2018NxStage Medical, Inc.

85,680 USD11SEC

3,500 shares@ US$24.482.0% of flowCommon StockSEC:0001246360-18-000793:1

◇

Winifred L. Swan

SVP and General CounselExecutives16 Jan 2018NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-18-000228:0

▼

Winifred L. Swan

SVP and General CounselExecutives16 Jan 2018NxStage Medical, Inc.

87,080 USD11SEC

3,500 shares@ US$24.882.0% of flowCommon StockSEC:0001246360-18-000228:1

◇

Winifred L. Swan

SVP and General CounselExecutives20 Dec 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-003339:0

▼

Winifred L. Swan

SVP and General CounselExecutives20 Dec 2017NxStage Medical, Inc.

88,725 USD11SEC

3,500 shares@ US$25.352.1% of flowCommon StockSEC:0001246360-17-003339:1

◇

Winifred L. Swan

SVP and General CounselExecutives15 Nov 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-003090:0

▼

Winifred L. Swan

SVP and General CounselExecutives15 Nov 2017NxStage Medical, Inc.

90,055 USD23SEC

3,500 shares@ US$25.732.2% of flowCommon StockSEC:0001246360-17-003090:1

▼

Winifred L. Swan

SVP and General CounselExecutives20 Oct 2017NxStage Medical, Inc.

96,250 USD26SEC

3,500 shares@ US$27.502.3% of flowCommon StockSEC:0001246360-17-002925:1

◇

Winifred L. Swan

SVP and General CounselExecutives20 Oct 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-002925:0

◇

Winifred L. Swan

SVP and General CounselExecutives20 Sept 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-002803:0

▼

Winifred L. Swan

SVP and General CounselExecutives20 Sept 2017NxStage Medical, Inc.

95,445 USD26SEC

3,500 shares@ US$27.272.3% of flowCommon StockSEC:0001246360-17-002803:1

◇

Winifred L. Swan

SVP and General CounselExecutives15 Aug 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-002578:0

▼

Winifred L. Swan

SVP and General CounselExecutives15 Aug 2017NxStage Medical, Inc.

102,235 USD26SEC

3,500 shares@ US$29.212.5% of flowCommon StockSEC:0001246360-17-002578:1

◇

Winifred L. Swan

SVP and General CounselExecutives20 Jul 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-002419:0

▼

Winifred L. Swan

SVP and General CounselExecutives20 Jul 2017NxStage Medical, Inc.

84,560 USD26SEC

3,500 shares@ US$24.162.1% of flowCommon StockSEC:0001246360-17-002419:1

◇

Winifred L. Swan

SVP and General CounselExecutives15 Jun 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.8% of flowCommon StockSEC:0001246360-17-002210:0

▼

Winifred L. Swan

SVP and General CounselExecutives15 Jun 2017NxStage Medical, Inc.

80,990 USD26SEC

3,500 shares@ US$23.142.1% of flowCommon StockSEC:0001246360-17-002210:1

◇

Winifred L. Swan

SVP and General CounselExecutives15 May 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.9% of flowCommon StockSEC:0001246360-17-001871:0

▼

Winifred L. Swan

SVP and General CounselExecutives15 May 2017NxStage Medical, Inc.

76,790 USD29SEC

3,500 shares@ US$21.942.0% of flowCommon StockSEC:0001246360-17-001871:1

◇

Winifred L. Swan

SVP and General CounselExecutives20 Apr 2017NxStage Medical, Inc.

33,090 USD11SEC

3,000 shares@ US$11.030.9% of flowCommon StockSEC:0001246360-17-001632:0

▼

Winifred L. Swan

SVP and General CounselExecutives20 Apr 2017NxStage Medical, Inc.

95,480 USD29SEC

3,500 shares@ US$27.282.5% of flowCommon StockSEC:0001246360-17-001632:1

25 of 250 declarations